MARKET

ERAS

ERAS

Erasca, Inc.
NASDAQ
16.01
+1.06
+7.09%
After Hours: 16.10 +0.09 +0.54% 19:56 06/26 EDT
OPEN
14.92
PREV CLOSE
14.95
HIGH
16.26
LOW
14.72
VOLUME
18.34M
TURNOVER
--
52 WEEK HIGH
24.28
52 WEEK LOW
1.210
MARKET CAP
4.98B
P/E (TTM)
-17.1634
1D
5D
1M
3M
1Y
5Y
1D
Erasca (ERAS) Could Be 40% Below Fair Value On Lawsuit And Trial Risk
Simply Wall St · 2d ago
Erasca, Inc. (ERAS) Faces Securities Class Action Amid Patient Death, Intellectual Property Questions, $2.8 Billion Market Cap Loss -- HBSS
PR Newswire · 3d ago
Verastem says KRAS G12D inhibitor VS-7375 shows early activity in Phase 1/2 TARGET-D 101 trial across solid tumors
PUBT · 4d ago
Erasca, Inc. (ERAS) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
PR Newswire · 4d ago
Erasca (ERAS) Is Down 5.3% After ERAS-0015 Lawsuits Raise Data, Safety And IP Concerns
Simply Wall St · 5d ago
Law Offices of Frank R. Cruz Encourages Erasca, Inc. (ERAS) Shareholders To Inquire About Securities Fraud Class Action
Barchart · 6d ago
Weekly Report: what happened at ERAS last week (0615-0619)?
Weekly Report · 6d ago
ERAS Investors Have Opportunity to Lead Erasca, Inc. Securities Fraud Lawsuit
PR Newswire · 6d ago
More
About ERAS
Erasca, Inc. is a clinical-stage precision oncology company. The Company is focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The Company has assembled RAS/MAPK pathway-focused pipeline in the industry, consisting of modality-agnostic programs aligned with its three therapeutic strategies of: targeting key upstream and downstream signaling nodes in the RAS/MAPK pathway; targeting RAS directly; and targeting escape routes that emerge in response to treatment. Its pipeline includes one clinical-stage program (a pan-RAF inhibitor), two IND-enabling stage programs (a pan-RAS molecular glue and a pan-KRAS inhibitor), and an additional discovery-stage program (an EGFR D2/D3 biparatopic antibody). Its lead product candidate is naporafenib, the Company initiated its SEACRAFT-2 pivotal Phase III trial for patients with NRAS-mutated (NRASm) melanoma.

Webull offers Erasca Inc stock information, including NASDAQ: ERAS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ERAS stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ERAS stock methods without spending real money on the virtual paper trading platform.